Bioptimus, a global AI company building the world's first world model for biology, today announced the launch of its Spatial ...
Xenium In Situ demonstrates higher transcript counts per gene in new comparison study of three spatial imaging platforms PLEASANTON, Calif., Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (TXG) ...
First fully integrated spatial multiomic assay from 10x Genomics (TXG) brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology PLEASANTON, Calif ...
PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal ...
After growing its Xenium In Situ single-cell spatial imaging platform into its third successful technology family last year, 10x Genomics has no plans for launching a fourth platform in 2024—but will ...
Spatial transcriptomics (ST) technologies reveal the spatial organization of gene expression in tissues, providing critical insights into development, neurobiology, and cancer. However, the high cost ...
Technological development is key to improving the way hematologic cancer is diagnosed and treated. With this vision, the Josep Carreras Leukemia Research Institute is committed to the creation and ...
Biological systems are inherently three-dimensional—tissues form intricate layers, networks, and architectures where cells interact in ways that extend far beyond a flat plane. To capture the true ...
PLEASANTON, Calif., Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a new non-peer-reviewed study has independently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results